2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
2 citations
,
March 2012 in “JAMA” Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.
2 citations
,
September 2011 in “Der Urologe” Prostate cancer prevention now focuses on healthy diets and some medications, not vitamins.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
Prescription and alternative therapies for hair loss will be compared for effectiveness.
1 citations
,
June 2025 in “European Journal of Clinical Pharmacology” Finasteride may increase the risk of suicidality and depression, especially in younger people.
1 citations
,
October 2023 in “Journal of the Endocrine Society” Finasteride may worsen blood sugar control in diabetic patients.
1 citations
,
September 2022 in “Problems of Endocrinology” Dutasteride shows promise as a potential treatment for Parkinson's disease.
1 citations
,
February 2022 in “The Journal of Urology” Certain drugs like Dutasteride and Finasteride might help fight SARS-CoV-2 by increasing levels of a steroid called DHEA, which can protect the heart and increase nitric oxide to counteract the virus.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
1 citations
,
September 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” Dihydrotestosterone (DHT) promotes the growth and spread of aggressive brain tumor cells.
1 citations
,
April 2020 in “Journal of The American Academy of Dermatology” 5ARI treatment improves hair growth in older men with minimal side effects.
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
1 citations
,
April 2016 in “The American Journal of the Medical Sciences” The document concludes that doctors should check for frontal fibrosing alopecia in patients with acquired hyperpigmentation and that early treatment is important.
1 citations
,
August 2015 in “Current Sexual Health Reports” 5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
1 citations
,
May 2012 in “Aktuelle Urologie” Chemoprevention, using drugs like finasteride and dutasteride, can help prevent prostate cancer.
March 2026 in “Actas Dermo-Sifiliográficas” Dermatologists in Spain now mostly prescribe oral minoxidil and dutasteride for hair loss.
February 2026 in “American Journal of Clinical Dermatology” Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
February 2026 in “NeuroSci” Finasteride and dutasteride may cause depression and anxiety, especially in younger men.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.